Neuroendocrinology News

The hormone cortisol and stress responses were suppressed with the consumption of sugar-sweetened beverages, according to recent study findings published in The Journal of Clinical Endocrinology & Metabolism.

Genomic maps of pediatric adrenocortical tumors have revealed aberrant genetic and chromosomal changes that drive cancer, along with the sequence of changes that trigger it, according to research published in Nature Communications.

Multiple interventions such as healthy eating habits, exercise and web-based cognitive training may prevent or postpone cognitive decline among older patients, according to data published in The Lancet.

The frequency of metastatic tumors from primary apparently sporadic tumors (AST) appears to increase with age, with a decreased metastatic interval observed compared with succinate dehydrogenase (SDHx) tumors, according to researchers.

SAN DIEGO — Surgery is important in managing some malignant pheochromocytomas and paragangliomas, according to a poster presented at The Endocrine Society annual meeting.

A drawing test could be a relatively easy way for clinicians to assess patient perceptions after long-term remission from acromegaly, according to research published in the European Journal of Endocrinology.

Adolescents with extreme obesity who underwent Roux-en-Y gastric bypass experienced energetic adaptations that favor weight regain, along with changes in insulin, adipokines, thyroid hormones, gut hormones and sympathetic nervous system activity, according to research published in Obesity.

Taking naps appears to release stress and deliver positive effects on immune responses, according to research published in The Journal of Clinical Endocrinology & Metabolism.

An oral therapeutic peptide helped patients with acromegaly control insulin-like growth factor-1 and growth hormone for up to 13 months after they switched from injectable somatostatin receptor ligands, according to research published in the Journal of Clinical Endocrinology & Metabolism.

Lanreotide demonstrated antitumor activity with a manageable safety profile in patients with pancreatic neuroendocrine tumors, according to a subgroup analysis of the CLARINET study presented at the Gastrointestinal Cancers Symposium.